Literature DB >> 17378840

The proportion of cores with high-grade prostatic intraepithelial neoplasia on extended-pattern needle biopsy is significantly associated with prostate cancer on site-directed repeat biopsy.

Ardavan Akhavan1, Jonathan D Keith, Sheldon I Bastacky, Chao Cai, Yun Wang, Joel B Nelson.   

Abstract

OBJECTIVE: To determine whether the predictive value of isolated high-grade prostatic intraepithelial neoplasia (HGPIN) for an unsampled prostate cancer on an extended biopsy is lower due to more thorough prostate sampling, and whether the proportion of cores with HGPIN is associated with prostate cancer, as isolated HGPIN on sextant prostate biopsy is associated with a 27-57% risk of prostate cancer on repeat biopsy. PATIENTS AND METHODS: All extended prostate biopsies taken by one urologist over 6 years were reviewed for patients with isolated HGPIN on initial biopsy. Biopsies were evaluated for histological features and the proportion of cores with HGPIN. The clinical characteristics and pathological findings from subsequent biopsies were determined.
RESULTS: Of 577 men having extended biopsies, 48 had isolated HGPIN, followed by one to four site-directed repeat biopsies. Although only 10 (21%) had cancer on the first repeat biopsy, overall 15 (31%) had cancer. Those with cancer on repeat biopsy had a significantly higher proportion of cores with HGPIN, i.e. 29% vs 15%, cancer vs no cancer, respectively (P = 0.04).
CONCLUSIONS: Isolated HGPIN on extended biopsy conferred a 31% risk of unsampled prostate cancer. The proportion of cores with HGPIN on initial biopsy was significantly associated with the risk of cancer. The same was not true for age, race, prostate-specific antigen level, or the findings on digital rectal examination. The significant association between the proportion of cores with HGPIN and the risk of cancer suggests that patients with unifocal HGPIN on extended biopsy be managed expectantly, whereas those with multifocal HGPIN be re-biopsied.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17378840     DOI: 10.1111/j.1464-410X.2006.06681.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  8 in total

1.  Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a high-risk cohort of men with negative initial prostate biopsies.

Authors:  Bruce J Trock; Michelle J Brotzman; Leslie A Mangold; Joseph W Bigley; Jonathan I Epstein; David McLeod; Eric A Klein; J Stephen Jones; Songbai Wang; Theresa McAskill; Jyoti Mehrotra; Bhargavi Raghavan; Alan W Partin
Journal:  BJU Int       Date:  2011-11-11       Impact factor: 5.588

Review 2.  What is the pathologist saying? Interpretation of the prostate pathology report.

Authors:  Omar Hameed
Journal:  Curr Urol Rep       Date:  2009-05       Impact factor: 3.092

Review 3.  Managing high-grade prostatic intraepithelial neoplasia (HGPIN) and atypical glands on prostate biopsy.

Authors:  Jeffrey J Tosoian; Ridwan Alam; Mark W Ball; H Ballentine Carter; Jonathan I Epstein
Journal:  Nat Rev Urol       Date:  2017-08-31       Impact factor: 14.432

Review 4.  Precursor lesions to prostatic adenocarcinoma.

Authors:  Jonathan I Epstein
Journal:  Virchows Arch       Date:  2008-12-02       Impact factor: 4.064

5.  High-grade prostatic intraepithelial neoplasia.

Authors:  Joseph C Klink; Ranko Miocinovic; Cristina Magi Galluzzi; Eric A Klein
Journal:  Korean J Urol       Date:  2012-05-18

6.  Risk of prostate cancer after detection of isolated high-grade prostatic intraepithelial neoplasia (HGPIN) on extended core needle biopsy: a UK hospital experience.

Authors:  Paras B Singh; Caroline M Nicholson; Narasimhan Ragavan; Rosemary A Blades; Francis L Martin; Shyam S Matanhelia
Journal:  BMC Urol       Date:  2009-05-27       Impact factor: 2.264

7.  Development and validation of risk score for predicting positive repeat prostate biopsy in patients with a previous negative biopsy in a UK population.

Authors:  Mark A Rochester; Nora Pashayan; Fiona Matthews; Andrew Doble; John McLoughlin
Journal:  BMC Urol       Date:  2009-07-16       Impact factor: 2.264

Review 8.  Risks of testosterone replacement therapy in men.

Authors:  E Charles Osterberg; Aaron M Bernie; Ranjith Ramasamy
Journal:  Indian J Urol       Date:  2014-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.